tamoxifen aziridine

Subscribe to Selected New Research on tamoxifen aziridine

11 relevant articles (0 outcomes, 0 trials/studies) found for this Bio-Agent

Description: estrogen receptor inactivator; structure given in first source

Also Known As:

Aziridine, 1-(2-(4-(1,2-diphenyl-1-butenyl)phenoxy)ethyl)-, (Z)-

Bio-Agent Context: Research Results

Organic Chemicals: 40

Hydrocarbons: 382

Cyclic Hydrocarbons: 2

Aromatic Hydrocarbons: 115

Benzene Derivatives: 9

Benzylidene Compounds

Stilbenes: 39

Tamoxifen: 7587

tamoxifen aziridine: 11

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/1996 - "Tamoxifen aziridine labeling of the estrogen receptor-potential utility in detecting biologically aggressive breast tumors." 11/01/1995 - "Recent investigation from our laboratory revealed that the estrogen receptor (ER) from breast cancer is characterized by a high molecular weight polymorphism: SDS-polyacrylamide gel electrophoresis of [3H]-tamoxifen aziridine ([3H]-TAZ) labeled cytosols usually display several bands corresponding to the native receptor (67 KDa) and lower molecular cleavage products" 08/20/1990 - "MCF-7 human breast cancer cells were submitted to the tritiated antiestrogen tamoxifen aziridine, frozen at -170 degrees C, stored and irradiated at -78 degrees C in a calibrated Gammacell 60Co irradiator" 10/01/1989 - "The denatured and nondenatured forms of the estrogen receptor (ER) in MCF-7 human breast cancer cells have been characterized by gel electrophoresis using the covalently attaching ligand [3H]tamoxifen aziridine ([3H]TA)" 11/06/1991 - "Comparison of tritiated estradiol and tamoxifen aziridine for measurement of estrogen receptors in human breast cancer cytosols." Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 11/06/1991 - "We failed to identify a specific [3H]tamoxifen aziridine electrophoretic pattern with respect to the tumor estrogen receptor content as measured by the dextran-coated charcoal assay" 11/06/1991 - "It will be clinically important to see whether the tumors positive for [3H]tamoxifen aziridine only correspond to the small subset of tumors (10%) which respond to tamoxifen treatment despite very low estrogen receptor levels, as measured by the dextran-coated charcoal technique." 12/01/1985 - "The effect of tamoxifen aziridine and tamoxifen (Tam), the parent compound which is an antiestrogen that binds reversibly to the estrogen receptor, were compared with respect to their effects on uterine growth, growth of dimethylbenzanthracene (DMBA)-induced mammary tumors in rats, and proliferation and plasminogen activator activity of MCF-7 human breast cancer cells" Get all the results and reference details, order at left...
3.	Carcinoma (Carcinomatosis) 06/01/1991 - "Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting techniques, enriched preparations of the natural anti-ER IgG subpopulation (IgGs) were found to specifically immunoprecipitate ER extracted from MCF-7 mammary carcinoma cells and to compete with [3H]tamoxifen-aziridine for ER binding" Get all the results and reference details, order at left...
3 Diseases and 11 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Estrogens (Estrogen)
2.	Estrogen Receptor Modulators (Antiestrogen)
3.	Tamoxifen
4.	Sodium Dodecyl Sulfate (Sodium Lauryl Sulfate)
5.	Estradiol (Estrace)
6.	9,10-Dimethyl-1,2-benzanthracene (DMBA)
7.	Urea (Carbamide)
8.	Sucrose (Saccharose)
9.	Estrogen Receptors
10.	Plasminogen Activators (Plasminogen Activator)
21 Drugs and Important Bio-Agents and 11 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>